SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 4.8% – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price fell 4.8% during trading on Monday . The company traded as low as $14.03 and last traded at $14.2650. 4,612,166 shares changed hands during trading, a decline of 46% from the average daily volume of 8,562,639 shares. The stock had previously closed at $14.98.

Analyst Ratings Changes

A number of research firms have recently commented on SLS. Maxim Group lifted their target price on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Trading Down 7.4%

The firm has a fifty day moving average of $8.11 and a two-hundred day moving average of $5.63. The company has a market cap of $2.73 billion, a PE ratio of -60.17 and a beta of 2.42.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SLS. Dagco Inc. bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth $2,177,000. Anson Funds Management LP raised its stake in shares of SELLAS Life Sciences Group by 2,093.8% during the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after purchasing an additional 5,757,938 shares during the period. Everhart Financial Group Inc. lifted its holdings in SELLAS Life Sciences Group by 40.8% during the 4th quarter. Everhart Financial Group Inc. now owns 466,216 shares of the company’s stock worth $1,758,000 after purchasing an additional 135,066 shares in the last quarter. World Investment Advisors bought a new position in SELLAS Life Sciences Group in the 4th quarter worth about $166,000. Finally, California State Teachers Retirement System boosted its stake in SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after purchasing an additional 1,709 shares during the period. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.